Works by Cater, Nilo B.

Results: 12

Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial.
Published in:
Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 583, doi. 10.1111/dom.16050
By:
- Cosentino, Francesco;
- Dagogo‐Jack, Samuel;
- Frederich, Robert;
- Cannon, Christopher P.;
- Cherney, David Z. I.;
- Mancuso, James P.;
- Wynant, Willy;
- Xing, Aiwen;
- Gantz, Ira;
- Cater, Nilo B.;
- Pratley, Richard E.
Publication type:
Article
Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV.
Published in:
Diabetes, Obesity & Metabolism, 2024, v. 26, n. 11, p. 5336, doi. 10.1111/dom.15895
By:
- Sridhar, Vikas S.;
- Cosentino, Francesco;
- Dagogo‐Jack, Samuel;
- McGuire, Darren K.;
- Pratley, Richard E.;
- Cater, Nilo B.;
- Noyes Essex, Margaret;
- Mancuso, James P.;
- Zhao, Yujie;
- Cherney, David Z. I.
Publication type:
Article
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
Published in:
Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1398, doi. 10.1111/dom.14965
By:
- Kim, Joseph M.;
- Bhatt, Deepak L.;
- Dagogo‐Jack, Samuel;
- Cherney, David Z. I.;
- Cosentino, Francesco;
- McGuire, Darren K.;
- Pratley, Richard E.;
- Liu, Chih‐Chin;
- Cater, Nilo B.;
- Frederich, Robert;
- Mancuso, James P.;
- Cannon, Christopher P.
Publication type:
Article
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin
Published in:
Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 758, doi. 10.1111/dom.14923
By:
- Corbin, Karen D.;
- Dagogo‐Jack, Samuel;
- Cannon, Christopher P.;
- Cherney, David Z.I.;
- Cosentino, Francesco;
- Frederich, Robert;
- Liu, Jie;
- Pong, Annpey;
- Lin, Jianxin;
- Cater, Nilo B.;
- Pratley, Richard E.
Publication type:
Article
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
Published in:
Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1829, doi. 10.1111/dom.14769
By:
- Segar, Matthew W.;
- Kolkailah, Ahmed A.;
- Frederich, Robert;
- Pong, Annpey;
- Cannon, Christopher P.;
- Cosentino, Francesco;
- Dagogo‐Jack, Samuel;
- McGuire, Darren K.;
- Pratley, Richard E.;
- Liu, Chih‐Chin;
- Maldonado, Mario;
- Liu, Jie;
- Cater, Nilo B.;
- Pandey, Ambarish;
- Cherney, David Z. I.
Publication type:
Article
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
Published in:
Diabetes, Obesity & Metabolism, 2020, v. 22, n. 4, p. 574, doi. 10.1111/dom.13931
By:
- Liu, Jie;
- Patel, Shrita;
- Cater, Nilo B.;
- Wu, Larry;
- Huyck, Susan;
- Terra, Steven G.;
- Hickman, Anne;
- Darekar, Amanda;
- Pong, Annpey;
- Gantz, Ira
Publication type:
Article
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
Published in:
European Heart Journal, 2023, v. 44, n. 48, p. 5163, doi. 10.1093/eurheartj/ehad639
By:
- Pandey, Ambarish;
- Kolkailah, Ahmed A;
- Cosentino, Francesco;
- Cannon, Christopher P;
- Frederich, Robert C;
- Cherney, David Z I;
- Dagogo-Jack, Samuel;
- Pratley, Richard E;
- Cater, Nilo B;
- Gantz, Ira;
- Mancuso, James P;
- McGuire, Darren K
Publication type:
Article
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.
Published in:
European Heart Journal, 2018, v. 39, n. 32, p. 2959, doi. 10.1093/eurheartj/ehy148
By:
- Ezekowitz, Michael D;
- Pollack, Charles V;
- Halperin, Jonathan L;
- England, Richard D;
- Nguyen, Sandra VanPelt;
- Spahr, Judith;
- Sudworth, Maria;
- Cater, Nilo B;
- Breazna, Andrei;
- Oldgren, Jonas
Publication type:
Article
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL).
Published in:
Annals of Medicine, 2008, v. 40, n. 6, p. 456, doi. 10.1080/07853890801964955
By:
- Holme, Ingar;
- Cater, Nilo B.;
- Faergeman, Ole;
- Kastelein, John J. P.;
- Olsson, Anders G.;
- Tikkanen, Matti J.;
- Lytken Larsen, Mogens;
- Lindahl, Christina;
- Pedersen, Terje R.;
- on behalf of the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering Study Group
Publication type:
Article
Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome<sup>*</sup>.
Published in:
Clinical Pharmacology & Therapeutics, 2003, v. 74, n. 3, p. 236, doi. 10.1016/S0009-9236(03)00170-X
By:
- Vega, Gloria Lena;
- Cater, Nilo B.;
- Hadizadeh, Dariusch R.;
- Meguro, Shinichi;
- Grundy, Scott M.
Publication type:
Article
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
Published in:
Sleep & Breathing, 2023, v. 27, n. 2, p. 669, doi. 10.1007/s11325-022-02594-2
By:
- Wojeck, Brian S.;
- Inzucchi, Silvio E.;
- Neeland, Ian J.;
- Mancuso, James P.;
- Frederich, Robert;
- Masiukiewicz, Urszula;
- Cater, Nilo B.;
- McGuire, Darren K.;
- Cannon, Christopher P.;
- Yaggi, Henry Klar
Publication type:
Article
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity.
Published in:
Diabetes Therapy, 2023, v. 14, n. 2, p. 319, doi. 10.1007/s13300-022-01345-6
By:
- Ji, Linong;
- Liu, Jie;
- Xu, Zhi Jin;
- Wei, Zhiqi;
- Zhang, Ruya;
- Malkani, Seema;
- Cater, Nilo B.;
- Frederich, Robert
Publication type:
Article